关于卫宁转债回售的第五次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：300253 证券简称：卫宁健康 公告编号：2025-035 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 特别提示 1、回售价格：100.281 元/张（含息、税） 2、回售条件满足日：2025 年 4 月 28 日 3、回售申报期：2025 年 5 月 12 日至 2025 年 5 月 16 日 4、发行人资金到账日：2025 年 5 月 21 日 5、回售款划拨日：2025 年 5 月 22 日 6、投资者回售款到账日：2025 年 5 月 23 日 7、回售申报期内，"卫宁转债"暂停转股 8、"卫宁转债"持有人有权选择是否进行回售，本次回售不具有 强制性 9、风险提示：持有人本次选择回售等同于以 100.281 元/张（含 当期利息）的价格卖出持有的"卫宁转债"。截至目前，"卫宁转债" 的收盘价格高于本次回售价格，投资者选择回售可能带来损失，敬请 投资者注意风险。 1、有条件回售条款 公司股票自 2025 年 3 月 16 日至 2 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-033 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 关于卫宁转债回售的第四次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、回售价格：100.281 元/张（含息、税） 2、回售条件满足日：2025 年 4 月 28 日 3、回售申报期：2025 年 5 月 12 日至 2025 年 5 月 16 日 4、发行人资金到账日：2025 年 5 月 21 日 5、回售款划拨日：2025 年 5 月 22 日 6、投资者回售款到账日：2025 年 5 月 23 日 7、回售申报期内，"卫宁转债"暂停转股 8、"卫宁转债"持有人有权选择是否进行回售，本次回售不具有 强制性 9、风险提示：持有人本次选择回售等同于以 100.281 元/张（含 当期利息）的价格卖出持有的"卫宁转债"。截至目前，"卫宁转债" 的收盘价格高于本次回售价格，投资者选择回售可能带来损失，敬请 投资者注意风险。 卫宁健康科技集团股份有限公司（以下简称"公司"）的股票自 2025 ...

关于召开 2024 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司于 2025 年 4 月 19 日在巨潮资讯 网上发布了《关于召开 2024 年度股东大会的通知》。本次会议将采取 现场投票与网络投票相结合的方式进行，现将会议有关事项提示如 下： 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会 证券代码：300253 证券简称：卫宁健康 公告编号：2025-034 卫宁健康科技集团股份有限公司 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：公司第六届董事会第十二次会议 审议通过了《关于提请召开公司 2024 年度股东大会的议案》。本次股 东大会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》等规定。 4、会议时间： （1）现场会议时间：2025 年 5 月 12 日（星期一）14:30 （2）网络投票时间：2025 年 5 月 12 日，其中： ①通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 5 月 12 日 9:15-9:25， ...

Investment Rating - The investment rating for the computer industry is "Buy" [2] Core Insights - The computer industry is experiencing a bottoming out of demand in 2024, with significant differences in structural performance across various segments. Companies are enhancing operational efficiency to cope with the challenges [6][14] - The median revenue growth rate for the industry in 2024 is -1.59%, a decrease of 4.88 percentage points from 2023. The median net profit growth rate is -2.24%, down 8.35 percentage points from the previous year [15] - The report highlights that while revenue and profit metrics are declining, the rate of decline is slowing, indicating potential for improvement in Q1 2025 [15][16] Summary by Sections 1. 2024 Annual Report: Bottoming Demand and Efficiency Improvements - The report analyzes the performance of 208 listed companies in the computer industry, revealing that the overall revenue growth is stabilizing, and profit margins are showing signs of recovery [14][15] - Different segments within the industry show varying performance, with IT hardware, trusted computing, and smart vehicle sectors demonstrating positive growth trends [16][28] 2. Demand Stabilization and Financial Indicators - The report notes that contract liabilities are beginning to improve, and accounts receivable growth is declining, indicating a more stable financial environment [23][24] - Cash inflows from sales of goods and services have significantly increased, reflecting a positive trend in operational cash flow [24] 3. Investment Activity and Valuation Levels - The report indicates an increase in net cash outflow from investment activities, suggesting an expansion trend among companies [26] - As of April 30, 2025, the industry’s price-to-earnings (P/E) ratio is 46 times, with software companies showing a higher P/E increase compared to hardware companies [19][20] 4. Key Areas of Investment Value - The report identifies several key areas with strong investment potential, including AI applications, domestic software and hardware replacements, and the smart driving industry [20][21] - The acceleration of domestic orders in trusted computing and the expansion of the Harmony OS ecosystem are expected to enhance the competitive edge of leading companies in the industry [20][21]

证券代码：300253 证券简称：卫宁健康 公告编号：2025-032 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 关于卫宁转债回售的第三次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、回售价格：100.281 元/张（含息、税） 2、回售条件满足日：2025 年 4 月 28 日 3、回售申报期：2025 年 5 月 12 日至 2025 年 5 月 16 日 4、发行人资金到账日：2025 年 5 月 21 日 5、回售款划拨日：2025 年 5 月 22 日 6、投资者回售款到账日：2025 年 5 月 23 日 7、回售申报期内，"卫宁转债"暂停转股 8、"卫宁转债"持有人有权选择是否进行回售，本次回售不具有 强制性 9、风险提示：持有人本次选择回售等同于以 100.281 元/张（含 当期利息）的价格卖出持有的"卫宁转债"。截至目前，"卫宁转债" 的收盘价格高于本次回售价格，投资者选择回售可能带来损失，敬请 投资者注意风险。 卫宁健康科技集团股份有限公司（以下简称"公司"）的股票自 2025 ...

Group 1 - The core products of Zhaoli Pharmaceutical show stable growth, with a high dividend payout ratio maintained, achieving a revenue of 2.578 billion yuan in 2024, a year-on-year increase of 32.71% [8][9] - The company has significantly reduced costs and improved efficiency, with a notable decrease in expense ratios, including a sales expense ratio of 32.53%, down 7.5 percentage points year-on-year [9] - The company plans to implement an employee stock ownership plan by the end of 2024, with profit growth targets set at no less than 30% for 2025 [10] Group 2 - Weining Health's revenue for Q1 2025 was 345 million yuan, a year-on-year decrease of 30.24%, with a net profit of 5.29 million yuan, down 68.18% [11][12] - The company is focusing on cost reduction and efficiency improvement, with a significant increase in cash flow from operating activities, up 120.53% year-on-year [12] - The WiNEX product is entering a phase of mass delivery, supporting internet operations and international adaptation, with a strong digital architecture capable of handling millions of transactions [14][15] Group 3 - Lais Information's revenue for 2024 was 1.61 billion yuan, a year-on-year decrease of 3.94%, while Q1 2025 revenue dropped by 55.53% to 109 million yuan [17][18] - The company is optimizing its business structure, with significant growth in air traffic control and urban traffic management sectors, achieving revenue increases of 13.68% and 33.47% respectively [18][19] - The company is enhancing its research and development efforts, with a focus on refining its product offerings and improving operational efficiency [20] Group 4 - FenJung Media reported a revenue of 12.262 billion yuan in 2024, a year-on-year increase of 3.01%, with a net profit of 5.155 billion yuan, up 6.80% [23][25] - The company maintains a high dividend payout ratio, with cash dividends amounting to 4.766 billion yuan, representing 92.45% of net profit [24][25] - The planned acquisition of New潮传媒 is expected to enhance the company's competitive position in the outdoor advertising market [28] Group 5 - Jingwang Electronics achieved a revenue of 12.659 billion yuan in 2024, a year-on-year increase of 17.68%, with a net profit of 1.169 billion yuan, up 24.86% [30][31] - The company is expanding its production capacity, with a focus on high-end markets and AI applications, particularly in the automotive sector [32][33] - The company is increasing its R&D investments to support technological advancements and market expansion [33]

Investment Rating - The report maintains an "Outperform" rating for the company [2][8][9] Core Insights - The company reported a revenue of 2.782 billion yuan in 2024, a decrease of 12.05% year-on-year, and a net profit attributable to shareholders of 88 million yuan, down 75.45% [7] - In Q1 2025, the company generated revenue of 345 million yuan, a decline of 30.24%, with a net profit of 5.29 million yuan, down 68.18% [7] - The short-term outlook for the medical IT sector remains under pressure, with the company facing challenges such as deferred customer demand and delays in project delivery [7] - The company is focusing on cost reduction and efficiency improvements, achieving a net cash flow from operating activities of 408 million yuan, an increase of 120.53% [7] - The WiNEX product is entering a rapid delivery phase, with multiple large hospitals adopting it and international projects being implemented [7] - The deployment of AI models is accelerating, with the company having deployed AI applications for over 20 users by the end of 2024, and an additional 80 users in the first quarter of 2025 [7] Financial Data and Profit Forecast - Total revenue forecast for 2025 is adjusted to 3.276 billion yuan, with a net profit forecast of 499 million yuan [6][8] - The company expects a revenue increase to 4.326 billion yuan and a net profit of 702 million yuan by 2027 [6][8] - The gross margin is projected to improve to 43.8% by 2027 [6] - The company’s PE ratio for 2025 is estimated at 45x [8][9]

证券代码：300253 证券简称：卫宁健康 公告编号：2025-031 债券代码：123104 债券简称：卫宁转债 2、回售条件满足日：2025 年 4 月 28 日 3、回售申报期：2025 年 5 月 12 日至 2025 年 5 月 16 日 4、发行人资金到账日：2025 年 5 月 21 日 卫宁健康科技集团股份有限公司 关于卫宁转债回售的第二次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、回售价格：100.281 元/张（含息、税） 5、回售款划拨日：2025 年 5 月 22 日 6、投资者回售款到账日：2025 年 5 月 23 日 7、回售申报期内，"卫宁转债"暂停转股 8、"卫宁转债"持有人有权选择是否进行回售，本次回售不具有 强制性 9、风险提示：持有人本次选择回售等同于以 100.281 元/张（含 当期利息）的价格卖出持有的"卫宁转债"。截至目前，"卫宁转债" 的收盘价格高于本次回售价格，投资者选择回售可能带来损失，敬请 投资者注意风险。 卫宁健康科技集团股份有限公司（以下简称"公司"）的股票自 2025 ...

Core Viewpoint - The company is experiencing short-term pressure on its performance, with a focus on cost reduction and efficiency improvement to enhance operational quality [2] Financial Performance - In Q1 2025, the company reported revenue of 345 million yuan, a year-on-year decrease of 30.24%, and a net profit attributable to shareholders of 5.29 million yuan, down 68.18% [1] - For the full year 2024, the company achieved revenue of 2.782 billion yuan, a decline of 12.05%, and a net profit of 88 million yuan, down 75.45% [1] Profitability Metrics - In Q1 2025, the gross margin and net margin were 34.46% and -0.97%, respectively, showing an increase of 0.75 percentage points and a decrease of 2.28 percentage points year-on-year [2] - For 2024, the gross margin and net margin were 41.68% and 1.80%, reflecting a decline of 3.32 percentage points and 8.24 percentage points year-on-year [2] Business Segments - The healthcare information technology segment generated revenue of 2.445 billion yuan in 2024, a decrease of 14.17%, accounting for 87.88% of total revenue [3] - The "Internet + Healthcare" segment showed growth, with revenue of 337 million yuan in 2024, up 7.83%, representing 12.11% of total revenue [3] Product Development - The WiNEX product has entered the mass delivery phase, supporting internet operations and international adaptation, with 75 core business systems achieving multilingual support [4] - The company is enhancing its AI capabilities with the release of WiNGPT2.8 and WiNEX Copilot2.1, deploying AI applications to over 20 users by the end of 2024 [5] Future Outlook - The company anticipates continued optimization of its organizational structure and personnel, with expectations for improved profitability driven by the demand for the new WiNEX product [2] - Revenue projections for 2025-2027 are estimated at 3.036 billion yuan, 3.343 billion yuan, and 3.715 billion yuan, with net profits of 305 million yuan, 374 million yuan, and 452 million yuan, respectively [5]

证券代码：300253 证券简称：卫宁健康 公告编号：2025-030 债券代码：123104 债券简称：卫宁转债 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、回售价格：100.281 元/张（含息、税） 2、回售条件满足日：2025 年 4 月 28 日 3、回售申报期：2025 年 5 月 12 日至 2025 年 5 月 16 日 4、发行人资金到账日：2025 年 5 月 21 日 5、回售款划拨日：2025 年 5 月 22 日 卫宁健康科技集团股份有限公司 关于卫宁转债回售的第一次提示性公告 6、投资者回售款到账日：2025 年 5 月 23 日 7、回售申报期内，"卫宁转债"暂停转股 一、回售事项概述 8、"卫宁转债"持有人有权选择是否进行回售，本次回售不具有 强制性 1、有条件回售条款 9、风险提示：持有人本次选择回售等同于以 100.281 元/张（含 当期利息）的价格卖出持有的"卫宁转债"。截至目前，"卫宁转债" 的收盘价格高于本次回售价格，投资者选择回售可能带来损失，敬请 投资者注意风险。 卫宁健康科技集团股份有限公司（ ...